MEDS (MEDS) Stock Analysis
Verdict: AVOID
Extremely distressed balance sheet ($42.5k cash) creates terminal dilution risk despite a speculative +275% spike on a $1.5M Helomics acquisition.
Investment score: 24/100
The model evaluates Wellgistics Health (MEDS) as a distressed micro-cap facing severe solvency risk. Despite a +274.7% price pop on the announcement of the Helomics AI acquisition, the underlying fundamentals exhibit a balance sheet with just $42,571 in cash against $29.8M in current liabilities, making immediate equity dilution almost mandatory.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| AHCO | -3.52 | 0.58 | 0.27 | 9.74 | — | -0.08 |
| ACH | -0.27 | -0.15 | 0.03 | 8.08 | — | -0.11 |
| EXHI | -583.33 | 0.00 | 181.95 | -447.54 | — | -0.41 |
| PDRX | -18.24 | 0.47 | 0.29 | 2.59 | — | -0.01 |
| ZSTK | -0.03 | 2.96 | 0.11 | -0.37 | — | -4.44 |